Related Experiment Video
Updated: Nov 9, 2025
11:51
Expansion and Enrichment of Gamma-Delta γδ T Cells from Apheresed Human Product
Published on: September 22, 2021
9.5K
Summary
The BNT3A antibody ICT01 activates unique antitumor gamma-delta T cells (γ9δ2 T cells) and directs them to tumors. Early clinical trial data in patients confirm these promising preclinical findings.
Area of Science:
- Immunology
- Oncology
- Clinical Trials
Background:
- Preclinical studies indicated that the BNT3A antibody ICT01 can activate and promote the migration of tumor-targeting gamma-delta T cells (γ9δ2 T cells).
- These findings suggested a potential therapeutic strategy for cancer treatment by harnessing the immune system.
Purpose of the Study:
- To evaluate the safety and preliminary efficacy of the monoclonal BNT3A antibody ICT01 in a first-in-human clinical trial.
- To confirm the activation and trafficking of γ9δ2 T cells to tumors in patients treated with ICT01.
Main Methods:
- A phase I/IIa, first-in-human clinical trial was conducted.
- Patients were treated with the monoclonal BNT3A antibody ICT01.
- Immune cell activation and trafficking were assessed in treated patients.
Main Results:
- Early data from the clinical trial demonstrated that ICT01 treatment led to the activation of unique antitumor γ9δ2 T cells.
- The results also indicated successful encouragement of γ9δ2 T cell trafficking to tumor sites in patients.
Conclusions:
- The monoclonal BNT3A antibody ICT01 shows potential as an immunotherapeutic agent for cancer.
- Clinical data support the preclinical observations of ICT01's mechanism of action involving γ9δ2 T cell activation and tumor trafficking.
Related Concept Videos
01:27Tumor Immunotherapy
816
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
816
01:27Cytotoxic T Cells-mediated Immune Response
5.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.7K
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K